Baseline characteristics
| Characteristic . | Value . |
|---|---|
| Median age (range), y | 63 (26-71) |
| Sex, female/male, n | 7/6 |
| Diagnosis, n | |
| Acute myeloid leukemia | 4 |
| Myelodysplastic syndrome | 3 |
| Non-Hodgkin lymphoma | 3 |
| Myeloproliferative disorder | 1 |
| Chronic lymphocytic leukemia | 1 |
| Myelofibrosis | 1 |
| Graft source, n | |
| Peripheral blood stem cells | 12 |
| Bone marrow | 1 |
| Donor, n | |
| Matched unrelated | 9 |
| Matched related | 2 |
| Haploidentical | 2 |
| Conditioning, n | |
| Reduced intensity | 10 |
| Myeloablative | 3 |
| GVHD prophylaxis, n | |
| Tacrolimus/sirolimus | 9 |
| Tacrolimus/methotrexate | 2 |
| Posttransplant cyclophosphamide plus tacrolimus/mycophenolate mofetil | 2 |
| Characteristic . | Value . |
|---|---|
| Median age (range), y | 63 (26-71) |
| Sex, female/male, n | 7/6 |
| Diagnosis, n | |
| Acute myeloid leukemia | 4 |
| Myelodysplastic syndrome | 3 |
| Non-Hodgkin lymphoma | 3 |
| Myeloproliferative disorder | 1 |
| Chronic lymphocytic leukemia | 1 |
| Myelofibrosis | 1 |
| Graft source, n | |
| Peripheral blood stem cells | 12 |
| Bone marrow | 1 |
| Donor, n | |
| Matched unrelated | 9 |
| Matched related | 2 |
| Haploidentical | 2 |
| Conditioning, n | |
| Reduced intensity | 10 |
| Myeloablative | 3 |
| GVHD prophylaxis, n | |
| Tacrolimus/sirolimus | 9 |
| Tacrolimus/methotrexate | 2 |
| Posttransplant cyclophosphamide plus tacrolimus/mycophenolate mofetil | 2 |